CY1124960T1 - Αντισωματα κατα του αυξητικου παραγοντα νευρων και μεθοδοι παρασκευης και χρησης αυτων - Google Patents
Αντισωματα κατα του αυξητικου παραγοντα νευρων και μεθοδοι παρασκευης και χρησης αυτωνInfo
- Publication number
- CY1124960T1 CY1124960T1 CY20221100091T CY221100091T CY1124960T1 CY 1124960 T1 CY1124960 T1 CY 1124960T1 CY 20221100091 T CY20221100091 T CY 20221100091T CY 221100091 T CY221100091 T CY 221100091T CY 1124960 T1 CY1124960 T1 CY 1124960T1
- Authority
- CY
- Cyprus
- Prior art keywords
- feline
- antibodies
- methods
- growth factor
- nerve growth
- Prior art date
Links
- 102000015336 Nerve Growth Factor Human genes 0.000 title abstract 4
- 108010025020 Nerve Growth Factor Proteins 0.000 title abstract 4
- 229940053128 nerve growth factor Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 241000282324 Felis Species 0.000 abstract 6
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 108091008604 NGF receptors Proteins 0.000 abstract 1
- 101150111783 NTRK1 gene Proteins 0.000 abstract 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Παρέχεται μία μέθοδος παρασκευής ενός αντισώματος κατάλληλου για χρήση σε ένα αιλουροειδές. Επίσης παρέχονται χιμαιρικά και αιλουροειδοποιημένα αντισώματα τα οποία συνδέονται ειδικά με αυξητικό παράγοντα νεύρων (NGF) αιλουροειδούς και εξουδετερώνουν την ικανότητα του NGF αιλουροειδούς να συνδέεται με τον υποδοχέα NGF αιλουροειδούς ρ75 ή TrkA. Η εφεύρεση επεκτείνεται σε νουκλεϊκά οξέα που κωδικεύουν αυτά και σε μεθόδους αγωγής του άλγους και της αρθρίτιδας σε ένα αιλουροειδές διά της χρήσης των εν λόγω αντισωμάτων και/ή νουκλεϊκών οξέων.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483488P | 2011-05-06 | 2011-05-06 | |
US201161531439P | 2011-09-06 | 2011-09-06 | |
EP12723731.1A EP2705055B1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
PCT/GB2012/051003 WO2012153122A1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124960T1 true CY1124960T1 (el) | 2023-01-05 |
Family
ID=79283336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100091T CY1124960T1 (el) | 2011-05-06 | 2022-02-02 | Αντισωματα κατα του αυξητικου παραγοντα νευρων και μεθοδοι παρασκευης και χρησης αυτων |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP4026845A1 (el) |
CY (1) | CY1124960T1 (el) |
DK (1) | DK3498732T3 (el) |
ES (1) | ES2905682T3 (el) |
FI (1) | FIC20220010I1 (el) |
FR (1) | FR22C1014I2 (el) |
HR (1) | HRP20211869T1 (el) |
HU (2) | HUE057288T2 (el) |
LT (2) | LT3498732T (el) |
NL (1) | NL301168I2 (el) |
NO (1) | NO2022008I1 (el) |
PL (1) | PL3498732T3 (el) |
PT (1) | PT3498732T (el) |
SI (1) | SI3498732T1 (el) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
JP2005514063A (ja) * | 2001-12-21 | 2005-05-19 | イデックス ラボラトリーズ インコーポレイテッド | イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法 |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
US20070191272A1 (en) | 2005-09-27 | 2007-08-16 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
EP2725037A1 (en) * | 2008-09-04 | 2014-04-30 | Vet Therapeutics, Inc. | Monoclonal antibodies binding canine CD20 |
HUE058226T2 (hu) * | 2010-08-19 | 2022-07-28 | Zoetis Belgium S A | NGF elleni antitestek és alkalmazásuk |
-
2012
- 2012-05-08 ES ES18205428T patent/ES2905682T3/es active Active
- 2012-05-08 HR HRP20211869TT patent/HRP20211869T1/hr unknown
- 2012-05-08 LT LTEP18205428.8T patent/LT3498732T/lt unknown
- 2012-05-08 EP EP21207684.8A patent/EP4026845A1/en active Pending
- 2012-05-08 SI SI201231979T patent/SI3498732T1/sl unknown
- 2012-05-08 DK DK18205428.8T patent/DK3498732T3/da active
- 2012-05-08 PL PL18205428T patent/PL3498732T3/pl unknown
- 2012-05-08 PT PT182054288T patent/PT3498732T/pt unknown
- 2012-05-08 HU HUE18205428A patent/HUE057288T2/hu unknown
-
2022
- 2022-02-02 CY CY20221100091T patent/CY1124960T1/el unknown
- 2022-03-30 LT LTPA2022005C patent/LTPA2022005I1/lt unknown
- 2022-04-04 NO NO2022008C patent/NO2022008I1/no unknown
- 2022-04-04 FI FIC20220010C patent/FIC20220010I1/fi unknown
- 2022-04-04 HU HUS2200012C patent/HUS2200012I1/hu unknown
- 2022-04-08 FR FR22C1014C patent/FR22C1014I2/fr active Active
- 2022-04-11 NL NL301168C patent/NL301168I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
DK3498732T3 (da) | 2022-01-17 |
NO2022008I1 (no) | 2022-04-04 |
HUE057288T2 (hu) | 2022-04-28 |
HRP20211869T1 (hr) | 2022-03-04 |
EP4026845A1 (en) | 2022-07-13 |
HUS2200012I1 (hu) | 2022-05-28 |
NL301168I2 (nl) | 2022-11-24 |
NL301168I1 (el) | 2022-04-13 |
ES2905682T3 (es) | 2022-04-11 |
SI3498732T1 (sl) | 2022-04-29 |
PT3498732T (pt) | 2022-02-02 |
PL3498732T3 (pl) | 2022-02-28 |
FIC20220010I1 (fi) | 2022-04-04 |
FR22C1014I2 (fr) | 2023-01-13 |
LT3498732T (lt) | 2022-01-10 |
LTPA2022005I1 (el) | 2022-04-25 |
FR22C1014I1 (fr) | 2022-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201320046D0 (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
MY161295A (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
GB201320050D0 (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
CY1124723T1 (el) | Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1124747T1 (el) | Ανθρωπινα αντισωματα σε pd-1 | |
CY1123534T1 (el) | Αντισωματα που περιλαμβανουν τροποποιημενες βαριες σταθερες περιοχες | |
CY1124787T1 (el) | Αντισωματα anti-gitr και μεθοδοι χρησης αυτων | |
BR112018014585A2 (pt) | receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii | |
CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
EA201600252A1 (ru) | Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования | |
GT201300149A (es) | Proteinas de union al tnf-a | |
EA201492149A1 (ru) | St2-антигенсвязывающие белки | |
CO7240399A2 (es) | Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos | |
DOP2013000178A (es) | Tratamiento de la osteoartritis y del dolor | |
EA201891410A1 (ru) | Антитела к с5 и способы их применения | |
CY1116792T1 (el) | Επιτοποι των il-17a και il-17f και αντισωματα ειδικα εναντι αυτων | |
EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
EA201792328A1 (ru) | Способ очистки белков | |
CY1122728T1 (el) | Αντισωματα εναντι hpa-1a | |
CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß | |
EA201491724A1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения | |
CY1124960T1 (el) | Αντισωματα κατα του αυξητικου παραγοντα νευρων και μεθοδοι παρασκευης και χρησης αυτων |